Chemokines as Therapeutic Targets in Cardiovascular Disease The Road Behind, The Road Ahead
Chemokines as Therapeutic Targets in Cardiovascular Disease The Road Behind, The Road Ahead
复制标题
趋化因子作为心血管疾病的治疗靶点
DOI：
10.1161/atvbaha.118.312037
复制
发表时间：
2019-04-01
影响因子：
8.7
通讯作者：
Koenen, Rory R.
中科院分区：
文献类型：
--
作者：
Noels, Heidi;Weber, Christian;Koenen, Rory R.
With the incidence and impact of atherosclerotic cardiovascular disease and its clinical manifestations still rising, therapeutic options that target the causal mechanisms of this disorder are highly desired. Since the CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) has demonstrated that lowering inflammation can be beneficial, focusing on mechanisms underlying inflammation, for example, leukocyte recruitment, is feasible. Being key orchestrators of leukocyte trafficking, chemokines have not lost their attractiveness as therapeutic targets, despite the difficult road to drug approval thus far. Still, innovative therapeutic approaches are being developed, paving the road towards the first chemokine-based therapeutic against inflammation. In this overview, recent developments for chemokines and for the chemokine-like factor MIF (macrophage migration inhibitory factor) will be discussed.
